Skip to main content
NCBI home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1985 Oct;143(4):485–497.

Prostaglandins, Thromboxanes and Leukotrienes in Clinical Medicine

Robert D Zipser 1, Giacomo Laffi 2
PMCID: PMC1306376  PMID: 3004043

Abstract

Although prostaglandin research began about 50 years ago, many of the most important advances in understanding the biochemistry, physiology and pharmacology have taken place within the past five to ten years. There is great potential for the extension of this research to the clinical practice of medicine. At this time, the most common interaction that clinicians have with the prostaglandin field is in administering nonsteroidal anti-inflammatory drugs, which function by inhibiting prostaglandins. The uses of these drugs include treating not only inflammation, but also dysmenorrhea, some renal disease, thrombotic diseases and some metabolic disorders. Prostaglandin analogs, with their potent effects on uterine contraction, are in common use in obstetrics. Other analogs, with gastric and duodenal cytoprotective effects are useful in treating peptic ulcer disease. Future benefits from prostaglandin and leukotriene research may include new therapy for inflammatory and hypersensitivity diseases such as asthma, inflammatory bowel diseases and dermatitis.

Full text

PDF
485

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson A. B., Haynes P. J., Guillebaud J., Turnbull A. C. Reduction of menstrual blood-loss by prostaglandin-synthetase inhibitors. Lancet. 1976 Apr 10;1(7963):774–776. doi: 10.1016/s0140-6736(76)91612-3. [DOI] [PubMed] [Google Scholar]
  2. Armstrong D. T., Grinwich D. L., Moon Y. S., Zamecnik J. Inhibition of ovulation in rabbits by intrafollicular injection of indomethacin and prostaglandin F antiserum. Life Sci. 1974 Jan 1;14(1):129–140. doi: 10.1016/0024-3205(74)90252-5. [DOI] [PubMed] [Google Scholar]
  3. BERGSTROEM S., DANIELSSON H., SAMUELSSON B. THE ENZYMATIC FORMATION OF PROSTAGLANDIN E2 FROM ARACHIDONIC ACID PROSTAGLANDINS AND RELATED FACTORS 32. Biochim Biophys Acta. 1964 Jul 15;90:207–210. doi: 10.1016/0304-4165(64)90145-x. [DOI] [PubMed] [Google Scholar]
  4. BROCKLEHURST W. E. The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock. J Physiol. 1960 Jun;151:416–435. doi: 10.1113/jphysiol.1960.sp006449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bach M. K. Prospects for the inhibition of leukotriene synthesis. Biochem Pharmacol. 1984 Feb 15;33(4):515–521. doi: 10.1016/0006-2952(84)90300-9. [DOI] [PubMed] [Google Scholar]
  6. Baracos V., Rodemann H. P., Dinarello C. A., Goldberg A. L. Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. N Engl J Med. 1983 Mar 10;308(10):553–558. doi: 10.1056/NEJM198303103081002. [DOI] [PubMed] [Google Scholar]
  7. Beisel W. R. Mediators of fever and muscle proteolysis. N Engl J Med. 1983 Mar 10;308(10):586–587. doi: 10.1056/NEJM198303103081009. [DOI] [PubMed] [Google Scholar]
  8. Belch J. J., McKay A., McArdle B., Leiberman P., Pollock J. G., Lowe G. D., Forbes C. D., Prentice C. R. Epoprostenol (prostacyclin) and severe arterial disease. A double-blind trial. Lancet. 1983 Feb 12;1(8320):315–317. doi: 10.1016/s0140-6736(83)91625-2. [DOI] [PubMed] [Google Scholar]
  9. Belch J. J., Newman P., Drury J. K., McKenzie F., Capell H., Leiberman P., Forbes C. D., Prentice C. R. Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial. Lancet. 1983 Feb 12;1(8320):313–315. doi: 10.1016/s0140-6736(83)91624-0. [DOI] [PubMed] [Google Scholar]
  10. Bisgaard H. Leukotrienes and prostaglandins in asthma. Allergy. 1984 Aug;39(6):413–420. doi: 10.1111/j.1398-9995.1984.tb01963.x. [DOI] [PubMed] [Google Scholar]
  11. Blackwell G. J., Carnuccio R., Di Rosa M., Flower R. J., Parente L., Persico P. Macrocortin: a polypeptide causing the anti-phospholipase effect of glucocorticoids. Nature. 1980 Sep 11;287(5778):147–149. doi: 10.1038/287147a0. [DOI] [PubMed] [Google Scholar]
  12. Bockman R. S. Prostaglandins in cancer: a review. Cancer Invest. 1983;1(6):485–493. doi: 10.3109/07357908309020274. [DOI] [PubMed] [Google Scholar]
  13. Borgeat P., Samuelsson B. Arachidonic acid metabolism in polymorphonuclear leukocytes: effects of ionophore A23187. Proc Natl Acad Sci U S A. 1979 May;76(5):2148–2152. doi: 10.1073/pnas.76.5.2148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Boyer T. D., Zia P., Reynolds T. B. Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology. 1979 Aug;77(2):215–222. [PubMed] [Google Scholar]
  15. Brain S., Camp R., Dowd P., Black A. K., Greaves M. The release of leukotriene B4-like material in biologically active amounts from the lesional skin of patients with psoriasis. J Invest Dermatol. 1984 Jul;83(1):70–73. doi: 10.1111/1523-1747.ep12261712. [DOI] [PubMed] [Google Scholar]
  16. Bukhave K., Rask-Madsen J. Saturation kinetics applied to in vitro effects of low prostaglandin E2 and F 2 alpha concentrations on ion transport across human jejunal mucosa. Gastroenterology. 1980 Jan;78(1):32–42. [PubMed] [Google Scholar]
  17. Bygdeman M., Fredricsson B., Svanborg K., Samuelsson B. The relation between fertility and prostaglandin content of seminal fluid in man. Fertil Steril. 1970 Aug;21(8):622–629. doi: 10.1016/s0015-0282(16)37687-7. [DOI] [PubMed] [Google Scholar]
  18. Caldwell B. V., Behrman H. R. Prostaglandins in reproductive processes. Med Clin North Am. 1981 Jul;65(4):927–936. doi: 10.1016/s0025-7125(16)31506-1. [DOI] [PubMed] [Google Scholar]
  19. Campieri M., Lanfranchi G. A., Bazzocchi G., Brignola C., Benatti A., Boccia S., Labo' G. Prostaglandins, indomethacin, and ulcerative colitis. Gastroenterology. 1980 Jan;78(1):193–193. [PubMed] [Google Scholar]
  20. Campieri M., Lanfranchi G. A., Bazzocehi G., Brignola C., Corazza G., Cortini C., Michelini M., Labó G. Salicylate other than 5-aminosalicylic acid ineffective in ulcerative colitis. Lancet. 1978 Nov 4;2(8097):993–993. doi: 10.1016/s0140-6736(78)92556-4. [DOI] [PubMed] [Google Scholar]
  21. Cannon P. J. Eicosanoids and the blood vessel wall. Circulation. 1984 Oct;70(4):523–528. doi: 10.1161/01.cir.70.4.523. [DOI] [PubMed] [Google Scholar]
  22. Carlson L. A., Ekelund L. G., Orö L. Clinical, metabolic and cardiovascular effects of different prostaglandins in man. Acta Med Scand. 1970 Dec;188(6):553–559. doi: 10.1111/j.0954-6820.1970.tb08082.x. [DOI] [PubMed] [Google Scholar]
  23. Casey L. C., Fletcher J. R., Zmudka M. I., Ramwell P. W. Prevention of endotoxin-induced pulmonary hypertension in primates by the use of a selective thromboxane synthetase inhibitor, OKY 1581. J Pharmacol Exp Ther. 1982 Aug;222(2):441–446. [PubMed] [Google Scholar]
  24. Chan W. Y. Prostaglandins and nonsteroidal antiinflammatory drugs in dysmenorrhea. Annu Rev Pharmacol Toxicol. 1983;23:131–149. doi: 10.1146/annurev.pa.23.040183.001023. [DOI] [PubMed] [Google Scholar]
  25. Christensen N. J., Gréen K. Endogenous prostaglandin synthesis and abortion. A mini-review. Acta Obstet Gynecol Scand Suppl. 1983;113:109–111. doi: 10.3109/00016348309155210. [DOI] [PubMed] [Google Scholar]
  26. Ciabattoni G., Cinotti G. A., Pierucci A., Simonetti B. M., Manzi M., Pugliese F., Barsotti P., Pecci G., Taggi F., Patrono C. Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin. N Engl J Med. 1984 Feb 2;310(5):279–283. doi: 10.1056/NEJM198402023100502. [DOI] [PubMed] [Google Scholar]
  27. Clark J. G., Kostal K. M., Marino B. A. Bleomycin-induced pulmonary fibrosis in hamsters. An alveolar macrophage product increases fibroblast prostaglandin E2 and cyclic adenosine monophosphate and suppresses fibroblast proliferation and collagen production. J Clin Invest. 1983 Dec;72(6):2082–2091. doi: 10.1172/JCI111173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Clive D. M., Stoff J. S. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1984 Mar 1;310(9):563–572. doi: 10.1056/NEJM198403013100905. [DOI] [PubMed] [Google Scholar]
  29. Cook J. A., Wise W. C., Halushka P. V. Elevated thromboxane levels in the rat during endotoxic shock: protective effects of imidazole, 13-azaprostanoic acid, or essential fatty acid deficiency. J Clin Invest. 1980 Jan;65(1):227–230. doi: 10.1172/JCI109655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Cooper I., Kelly R. W. The measurement of E and 19-hydroxy E prostaglandins in human seminal plasma. Prostaglandins. 1975 Sep;10(3):507–514. doi: 10.1016/0090-6980(75)90131-8. [DOI] [PubMed] [Google Scholar]
  31. Craven P. A., Saito R., DeRubertis F. R. Role of local prostaglandin synthesis in the modulation of proliferative activity of rat colonic epithelium. J Clin Invest. 1983 Oct;72(4):1365–1375. doi: 10.1172/JCI111093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Cummings J. H., Newman A., Misiewicz J. J., Milton-Thompson G. J., Billings J. A. Effect of intravenous prostaglandin F 2 on small intestinal function in man. Nature. 1973 May 18;243(5403):169–171. doi: 10.1038/243169a0. [DOI] [PubMed] [Google Scholar]
  33. Cuthbert M. F. Effect on airways resistance of prostaglandin E1 given by aerosol to healthy and asthmatic volunteers. Br Med J. 1969 Dec 20;4(5685):723–726. doi: 10.1136/bmj.4.5685.723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Dahlén S. E., Hansson G., Hedqvist P., Björck T., Granström E., Dahlén B. Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotrienes C4, D4, and E4. Proc Natl Acad Sci U S A. 1983 Mar;80(6):1712–1716. doi: 10.1073/pnas.80.6.1712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Dahlén S. E., Hedqvist P., Hammarström S., Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature. 1980 Dec 4;288(5790):484–486. doi: 10.1038/288484a0. [DOI] [PubMed] [Google Scholar]
  36. Dawson W., Lewis R. L., McMahon R. E., Sweatman W. J. Potent bronchoconstrictor activity of 15-keto prostaglandin F2alpha. Nature. 1974 Jul 26;250(464):331–332. doi: 10.1038/250331a0. [DOI] [PubMed] [Google Scholar]
  37. Demers L. M., Allegra J. C., Harvey H. A., Lipton A., Luderer J. R., Mortel R., Brenner D. E. Plasma prostaglandins in hypercalcemic patients with neoplastic disease. Cancer. 1977 Apr;39(4):1559–1562. doi: 10.1002/1097-0142(197704)39:4<1559::aid-cncr2820390430>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  38. Demling R. H. Role of prostaglandins in acute pulmonary microvascular injury. Ann N Y Acad Sci. 1982;384:517–534. doi: 10.1111/j.1749-6632.1982.tb21397.x. [DOI] [PubMed] [Google Scholar]
  39. Dennefors B., Hamberger L., Hillensjö T., Holmes P., Janson P. O., Magnusson C., Nilsson L. Aspects concerning the role of prostaglandins for ovarian function. Acta Obstet Gynecol Scand Suppl. 1983;113:31–41. doi: 10.3109/00016348309155194. [DOI] [PubMed] [Google Scholar]
  40. Di Rosa M., Flower R. J., Hirata F., Parente L., Russo-Marie F. Anti-phospholipase proteins. Prostaglandins. 1984 Oct;28(4):441–442. doi: 10.1016/0090-6980(84)90232-6. [DOI] [PubMed] [Google Scholar]
  41. Donadio J. V., Jr, Anderson C. F., Mitchell J. C., 3rd, Holley K. E., Ilstrup D. M., Fuster V., Chesebro J. H. Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy. N Engl J Med. 1984 May 31;310(22):1421–1426. doi: 10.1056/NEJM198405313102203. [DOI] [PubMed] [Google Scholar]
  42. Doppelt S. H., Slovik D. M., Neer R. M., Nolan J., Zusman R. M., Potts J. T., Jr Gut-mediated hypercalcemia in rabbits bearing VX2 carcinoma: new mechanism for tumor-induced hypercalcemia. Proc Natl Acad Sci U S A. 1982 Jan;79(2):640–644. doi: 10.1073/pnas.79.2.640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Dowd P. M., Martin M. F., Cooke E. D., Bowcock S. A., Jones R., Dieppe P. A., Kirby J. D. Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2). Br J Dermatol. 1982 Jan;106(1):81–89. doi: 10.1111/j.1365-2133.1982.tb00905.x. [DOI] [PubMed] [Google Scholar]
  44. Drazen J. M., Austen K. F., Lewis R. A., Clark D. A., Goto G., Marfat A., Corey E. J. Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci U S A. 1980 Jul;77(7):4354–4358. doi: 10.1073/pnas.77.7.4354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Dyerberg J., Bang H. O., Stoffersen E., Moncada S., Vane J. R. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet. 1978 Jul 15;2(8081):117–119. doi: 10.1016/s0140-6736(78)91505-2. [DOI] [PubMed] [Google Scholar]
  46. Dzau V. J., Packer M., Lilly L. S., Swartz S. L., Hollenberg N. K., Williams G. H. Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia. N Engl J Med. 1984 Feb 9;310(6):347–352. doi: 10.1056/NEJM198402093100603. [DOI] [PubMed] [Google Scholar]
  47. Eichner E. R. Platelets, carotids, and coronaries. Critique on antithrombotic role of antiplatelet agents, exercise, and certain diets. Am J Med. 1984 Sep;77(3):513–523. doi: 10.1016/0002-9343(84)90113-x. [DOI] [PubMed] [Google Scholar]
  48. Ellwood D. A., Mitchell M. D., Anderson A. B., Turnbull A. C. Oestrogens, prostaglandins, and cervical ripening. Lancet. 1979 Feb 17;1(8112):376–377. doi: 10.1016/s0140-6736(79)92909-x. [DOI] [PubMed] [Google Scholar]
  49. Feldberg W., Kellaway C. H. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J Physiol. 1938 Nov 14;94(2):187–226. doi: 10.1113/jphysiol.1938.sp003674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Ferris T. F. Prostaglandins and the kidney. Am J Nephrol. 1983 Mar-Jun;3(2-3):139–144. doi: 10.1159/000166703. [DOI] [PubMed] [Google Scholar]
  51. Fichman M. P., Telfer N., Zia P., Speckart P., Golub M., Rude R. Role of prostaglandins in the pathogenesis of Bartter's syndrome. Am J Med. 1976 May 31;60(6):785–797. doi: 10.1016/0002-9343(76)90892-5. [DOI] [PubMed] [Google Scholar]
  52. Fiedler L. PGF2 alpha--a new therapy for paralytic ileus? Adv Prostaglandin Thromboxane Res. 1980;8:1609–1610. [PubMed] [Google Scholar]
  53. FitzGerald G. A., Brash A. R., Falardeau P., Oates J. A. Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest. 1981 Nov;68(5):1272–1276. doi: 10.1172/JCI110373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. FitzGerald G. A., Oates J. A., Hawiger J., Maas R. L., Roberts L. J., 2nd, Lawson J. A., Brash A. R. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983 Mar;71(3):676–688. doi: 10.1172/JCI110814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. FitzGerald G. A., Pedersen A. K., Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation. 1983 Jun;67(6):1174–1177. doi: 10.1161/01.cir.67.6.1174. [DOI] [PubMed] [Google Scholar]
  56. FitzGerald G. A., Smith B., Pedersen A. K., Brash A. R. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med. 1984 Apr 26;310(17):1065–1068. doi: 10.1056/NEJM198404263101701. [DOI] [PubMed] [Google Scholar]
  57. Fletcher J. R. Prostaglandin synthetase inhibitors in endotoxin or septic shock--a review. Adv Shock Res. 1983;10:9–14. [PubMed] [Google Scholar]
  58. Flower R. J. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev. 1974 Mar;26(1):33–67. [PubMed] [Google Scholar]
  59. Foegh M. L., Winchester J. F., Zmudka M., Helfrich G. B., Cooley C., Ramwell P. W., Schreiner G. E. Urine i-TXB2 in renal allograft rejection. Lancet. 1981 Aug 29;2(8244):431–434. doi: 10.1016/s0140-6736(81)90772-8. [DOI] [PubMed] [Google Scholar]
  60. Freeman R. H., Davis J. O., Villarreal D. Role of renal prostaglandins in the control of renin release. Circ Res. 1984 Jan;54(1):1–9. doi: 10.1161/01.res.54.1.1. [DOI] [PubMed] [Google Scholar]
  61. Fridovich I. The biology of oxygen radicals. Science. 1978 Sep 8;201(4359):875–880. doi: 10.1126/science.210504. [DOI] [PubMed] [Google Scholar]
  62. Friedman W. F., Hirschklau M. J., Printz M. P., Pitlick P. T., Kirkpatrick S. E. Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med. 1976 Sep 2;295(10):526–529. doi: 10.1056/NEJM197609022951003. [DOI] [PubMed] [Google Scholar]
  63. Frolich J. C., Sweetman B. J., Carr K., Hollifield J. W., Oates J. A. Assessment of the levels of pga2 in human plasma by gas chromatography-mass spectrometry. Prostaglandins. 1975 Jul;10(1):185–195. doi: 10.1016/0090-6980(75)90103-3. [DOI] [PubMed] [Google Scholar]
  64. Garcia-Perez A., Smith W. L. Apical-basolateral membrane asymmetry in canine cortical collecting tubule cells. Bradykinin, arginine vasopressin, prostaglandin E2 interrelationships. J Clin Invest. 1984 Jul;74(1):63–74. doi: 10.1172/JCI111419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Garella S., Matarese R. A. Renal effects of prostaglandins and clinical adverse effects of nonsteroidal anti-inflammatory agents. Medicine (Baltimore) 1984 May;63(3):165–181. doi: 10.1097/00005792-198405000-00003. [DOI] [PubMed] [Google Scholar]
  66. Gentilini P., Laffi G., Buzzelli G., Stefani P., Scarpelli P., Paladini S., Smorlesi C., La Villa G., Forti G. Functional renal alterations in chronic liver diseases. Digestion. 1980;20(2):73–78. doi: 10.1159/000198421. [DOI] [PubMed] [Google Scholar]
  67. Gerber J. G. Indomethacin-induced rises in blood pressure. Ann Intern Med. 1983 Oct;99(4):555–558. doi: 10.7326/0003-4819-99-4-555. [DOI] [PubMed] [Google Scholar]
  68. Gerber J. G., Olson R. D., Nies A. S. Interrelationship between prostaglandins and renin release. Kidney Int. 1981 Jun;19(6):816–821. doi: 10.1038/ki.1981.85. [DOI] [PubMed] [Google Scholar]
  69. Gerber J. G. Role of prostaglandins in the hemodynamic and tubular effects of furosemide. Fed Proc. 1983 Apr;42(6):1707–1710. [PubMed] [Google Scholar]
  70. Gill J. R., Jr, Bartter F. C. Evidence for a prostaglandin-independent defect in chloride reabsorption in the loop of Henle as a proximal cause of Bartter's syncrome. Am J Med. 1978 Nov;65(5):766–772. doi: 10.1016/0002-9343(78)90794-5. [DOI] [PubMed] [Google Scholar]
  71. Gimbrone M. A., Jr, Brock A. F., Schafer A. I. Leukotriene B4 stimulates polymorphonuclear leukocyte adhesion to cultured vascular endothelial cells. J Clin Invest. 1984 Oct;74(4):1552–1555. doi: 10.1172/JCI111570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Gimson A. E., Langley P. G., Hughes R. D., Canalese J., Mellon P. J., Williams R., Woods H. F., Weston M. J. Prostacyclin to prevent platelet activation during charcoal haemoperfusion in fulminant hepatic failure. Lancet. 1980 Jan 26;1(8161):173–175. doi: 10.1016/s0140-6736(80)90661-3. [DOI] [PubMed] [Google Scholar]
  73. Goldblatt M. W. Properties of human seminal plasma. J Physiol. 1935 May 13;84(2):208–218. doi: 10.1113/jphysiol.1935.sp003269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Goldin E., Rachmilewitz D. Prostanoids cytoprotection for maintaining remission in ulcerative colitis. Failure of 15(R), 15-methylprostaglandin E2. Dig Dis Sci. 1983 Sep;28(9):807–811. doi: 10.1007/BF01296903. [DOI] [PubMed] [Google Scholar]
  75. Goldstein R. H., Miller K., Glassroth J., Linscott R., Snider G. L., Franzblau C., Polgar P. Influence of asbestos fibers on collagen and prostaglandin production in fibroblast and macrophage co-cultures. J Lab Clin Med. 1982 Nov;100(5):778–785. [PubMed] [Google Scholar]
  76. Goodwin J. S., Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol. 1983 Oct;3(4):295–315. doi: 10.1007/BF00915791. [DOI] [PubMed] [Google Scholar]
  77. Goodwin J. S. Immunologic effects of nonsteroidal anti-inflammatory drugs. Am J Med. 1984 Oct 15;77(4B):7–15. doi: 10.1016/s0002-9343(84)80086-8. [DOI] [PubMed] [Google Scholar]
  78. Goodwin J. S., Messner R. P., Bankhurst A. D., Peake G. T., Saiki J. H., Williams R. C., Jr Prostaglandin-producing suppressor cells in Hodgkin's disease. N Engl J Med. 1977 Nov 3;297(18):963–968. doi: 10.1056/NEJM197711032971802. [DOI] [PubMed] [Google Scholar]
  79. Gordon D., Bray M. A., Morley J. Control of lymphokine secretion by prostaglandins. Nature. 1976 Jul 29;262(5567):401–402. doi: 10.1038/262401a0. [DOI] [PubMed] [Google Scholar]
  80. Gots R. E., Formal S. B., Giannella R. A. Indomethacin inhibition of Salmonella typhimurium, Shigella flexneri, and cholera-mediated rabbit ileal secretion. J Infect Dis. 1974 Sep;130(3):280–284. doi: 10.1093/infdis/130.3.280. [DOI] [PubMed] [Google Scholar]
  81. Goyal R. K. Deleterious effects of prostaglandins on esophageal mucosa. Gastroenterology. 1980 May;78(5 Pt 1):1085–1100. [PubMed] [Google Scholar]
  82. Granström E., Kindahl H. Radioimmunoassay of prostaglandins and thromboxanes. Adv Prostaglandin Thromboxane Res. 1978;5:119–210. [PubMed] [Google Scholar]
  83. Granström E., Kindahl H., Swahn M. L. Profiles of prostaglandin metabolites in the human circulation. Identification of late-appearing, long-lived products. Biochim Biophys Acta. 1982 Oct 14;713(1):46–60. doi: 10.1016/0005-2760(82)90165-5. [DOI] [PubMed] [Google Scholar]
  84. Griffin M., Weiss J. W., Leitch A. G., McFadden E. R., Jr, Corey E. J., Austen K. F., Drazen J. M. Effects of leukotriene D on the airways in asthma. N Engl J Med. 1983 Feb 24;308(8):436–439. doi: 10.1056/NEJM198302243080807. [DOI] [PubMed] [Google Scholar]
  85. Gryglewski R. J., Nowak S., Kostka-Trabka E., Kusmiderski J., Dembinska-Kiec A., Bieron K., Basista M., Blaszczyk B. Treatment of ischaemic stroke with prostacyclin. Stroke. 1983 Mar-Apr;14(2):197–202. doi: 10.1161/01.str.14.2.197. [DOI] [PubMed] [Google Scholar]
  86. Halushka P. V., Rogers R. C., Loadholt C. B., Colwell J. A. Increased platelet thromboxane synthesis in diabetes mellitus. J Lab Clin Med. 1981 Jan;97(1):87–96. [PubMed] [Google Scholar]
  87. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2994–2998. doi: 10.1073/pnas.72.8.2994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Hammarström S., Hamberg M., Samuelsson B., Duell E. A., Stawiski M., Voorhees J. J. Increased concentrations of nonesterified arachidonic acid, 12L-hydroxy-5,8,10,14-eicosatetraenoic acid, prostaglandin E2, and prostaglandin F2alpha in epidermis of psoriasis. Proc Natl Acad Sci U S A. 1975 Dec;72(12):5130–5134. doi: 10.1073/pnas.72.12.5130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Hammarström S. Leukotrienes. Annu Rev Biochem. 1983;52:355–377. doi: 10.1146/annurev.bi.52.070183.002035. [DOI] [PubMed] [Google Scholar]
  90. Harlan J. M., Harker L. A. Hemostasis, thrombosis, and thromboembolic disorders. The role of arachidonic acid metabolites in platelet-vessel wall interactions. Med Clin North Am. 1981 Jul;65(4):855–880. doi: 10.1016/s0025-7125(16)31502-4. [DOI] [PubMed] [Google Scholar]
  91. Hechtman H. B., Huval W. V., Mathieson M. A., Stemp L. I., Valeri C. R., Shepro D. Prostaglandin and thromboxane mediation of cardiopulmonary failure. Surg Clin North Am. 1983 Apr;63(2):263–283. doi: 10.1016/s0039-6109(16)42981-6. [DOI] [PubMed] [Google Scholar]
  92. Henrich W. L. Role of prostaglandins in renin secretion. Kidney Int. 1981 Jun;19(6):822–830. doi: 10.1038/ki.1981.86. [DOI] [PubMed] [Google Scholar]
  93. Heymann M. A. Pharmacologic use of prostaglandin E1 in infant with congenital heart disease. Am Heart J. 1981 Jun;101(6):837–843. doi: 10.1016/0002-8703(81)90622-0. [DOI] [PubMed] [Google Scholar]
  94. Heymann M. A., Rudolph A. M., Silverman N. H. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med. 1976 Sep 2;295(10):530–533. doi: 10.1056/NEJM197609022951004. [DOI] [PubMed] [Google Scholar]
  95. Higashihara E., Stokes J. B., Kokko J. P., Campbell W. B., DuBose T. D., Jr Cortical and papillary micropuncture examination of chloride transport in segments of the rat kidney during inhibition of prostaglandin production. Possible role for prostaglandins in the chloruresis of acute volume expansion. J Clin Invest. 1979 Nov;64(5):1277–1287. doi: 10.1172/JCI109583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Hirata F. The regulation of lipomodulin, a phospholipase inhibitory protein, in rabbit neutrophils by phosphorylation. J Biol Chem. 1981 Aug 10;256(15):7730–7733. [PubMed] [Google Scholar]
  97. Hollander D., Tarnawski A., Gergely H., Zipser R. D. Sucralfate protection of the gastric mucosa against ethanol-induced injury: a prostaglandin-mediated process? Scand J Gastroenterol Suppl. 1984;101:97–102. [PubMed] [Google Scholar]
  98. Hong S. L., Levine L. Inhibition of arachidonic acid release from cells as the biochemical action of anti-inflammatory corticosteroids. Proc Natl Acad Sci U S A. 1976 May;73(5):1730–1734. doi: 10.1073/pnas.73.5.1730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Honn K. V., Menter D., Cavanaugh P. G., Neagos G., Moilanen D., Taylor J. D., Sloane B. F. A review of prostaglandins and the treatment of tumor metastasis. Acta Clin Belg. 1983;38(1):53–67. doi: 10.1080/22953337.1983.11718906. [DOI] [PubMed] [Google Scholar]
  100. Horton E. W., Main I. H., Thompson C. J., Wright P. M. Effect of orally administered prostaglandin E1 on gastric secretion and gastrointestinal motility in man. Gut. 1968 Dec;9(6):655–658. doi: 10.1136/gut.9.6.655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Horton E. W., Poyser N. L. Uterine luteolytic hormone: a physiological role for prostaglandin F2alpha. Physiol Rev. 1976 Oct;56(4):595–651. doi: 10.1152/physrev.1976.56.4.595. [DOI] [PubMed] [Google Scholar]
  102. Horton R., Zipser R., Fichman M. Prostaglandins, renal function and vascular regulation. Med Clin North Am. 1981 Jul;65(4):891–914. doi: 10.1016/s0025-7125(16)31504-8. [DOI] [PubMed] [Google Scholar]
  103. Hossman V., Heinen A., Auel H., FitzGerald G. A. A randomized, placebo controlled trial of prostacyclin (PGI2) in peripheral arterial disease. Thromb Res. 1981 May 15;22(4):481–490. doi: 10.1016/0049-3848(81)90109-2. [DOI] [PubMed] [Google Scholar]
  104. Hyman A. L., Mathé A. A., Lippton H. L., Kadowitz P. J. Prostaglandins and the lung. Med Clin North Am. 1981 Jul;65(4):789–808. doi: 10.1016/s0025-7125(16)31498-5. [DOI] [PubMed] [Google Scholar]
  105. Ishizaki T., Miyabo S., Mifune J., Koshino T., Ono S., Nakayama A., Tanaka T. OP-1206, a prostaglandin E1 derivative. Effects of oral administration to patients with chronic lung disease. Chest. 1984 Mar;85(3):382–386. doi: 10.1378/chest.85.3.382. [DOI] [PubMed] [Google Scholar]
  106. Jacobs E. R., Bone R. C. Mediators of septic lung injury. Med Clin North Am. 1983 May;67(3):701–715. doi: 10.1016/s0025-7125(16)31198-1. [DOI] [PubMed] [Google Scholar]
  107. Jones T. R., Davis C., Daniel E. E. Pharmacological study of the contractile activity of leukotriene C4 and D4 on isolated human airway smooth muscle. Can J Physiol Pharmacol. 1982 May;60(5):638–643. doi: 10.1139/y82-087. [DOI] [PubMed] [Google Scholar]
  108. Kadowitz P. J., Joiner P. D., Hyman A. L. Effect of prostaglandin E2 on pulmonary vascular resistance in intact dog, swine and lamb. Eur J Pharmacol. 1975 Mar;31(1):72–80. doi: 10.1016/0014-2999(75)90080-1. [DOI] [PubMed] [Google Scholar]
  109. Kajanoja P. Induction of abortion by prostaglandins in the second trimester of pregnancy. A review. Acta Obstet Gynecol Scand Suppl. 1983;113:145–151. doi: 10.3109/00016348309155217. [DOI] [PubMed] [Google Scholar]
  110. Karim S. M., Filshie G. M. Therapeutic abortion using prostaglandin F2alpha. Lancet. 1970 Jan 24;1(7639):157–159. doi: 10.1016/s0140-6736(70)90402-2. [DOI] [PubMed] [Google Scholar]
  111. Karim S. M., Trussell R. R., Patel R. C., Hillier K. Response of pregnant human uterus to prostaglandin-F2-alpha-induction of labour. Br Med J. 1968 Dec 7;4(5631):621–623. doi: 10.1136/bmj.4.5631.621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Kimberg D. V., Field M., Gershon E., Henderson A. Effects of prostaglandins and cholera enterotoxin on intestinal mucosal cyclic AMP accumulation. Evidence against an essential role for prostaglandins in the action of toxin. J Clin Invest. 1974 Mar;53(3):941–949. doi: 10.1172/JCI107635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  113. Kimberly R. P., Plotz P. H. Aspirin-induced depression of renal function. N Engl J Med. 1977 Feb 24;296(8):418–424. doi: 10.1056/NEJM197702242960803. [DOI] [PubMed] [Google Scholar]
  114. Klickstein L. B., Shapleigh C., Goetzl E. J. Lipoxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthritis. J Clin Invest. 1980 Nov;66(5):1166–1170. doi: 10.1172/JCI109947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  115. Klotz T. A., Cohn L. S., Zipser R. D. Urinary excretion of thromboxane B2 in patients with venous thromboembolic disease. Chest. 1984 Mar;85(3):329–335. doi: 10.1378/chest.85.3.329. [DOI] [PubMed] [Google Scholar]
  116. Korman S. H., Berant M., Alon U. Review: prostaglandins in diarrheal states. Isr J Med Sci. 1981 Dec;17(12):1109–1113. [PubMed] [Google Scholar]
  117. Korn J. H., Halushka P. V., LeRoy E. C. Mononuclear cell modulation of connective tissue function: suppression of fibroblast growth by stimulation of endogenous prostaglandin production. J Clin Invest. 1980 Feb;65(2):543–554. doi: 10.1172/JCI109698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  118. Kuehl F. A., Jr, Humes J. L., Egan R. W., Ham E. A., Beveridge G. C., Van Arman C. G. Role of prostaglandin endoperoxide PGG2 in inflammatory processes. Nature. 1977 Jan 13;265(5590):170–173. doi: 10.1038/265170a0. [DOI] [PubMed] [Google Scholar]
  119. Lands W. E. The biosynthesis and metabolism of prostaglandins. Annu Rev Physiol. 1979;41:633–652. doi: 10.1146/annurev.ph.41.030179.003221. [DOI] [PubMed] [Google Scholar]
  120. Lange A. P., Westergaard J. G., Secher N. J., Pedersen G. T. Labor induction with prostaglandins. Acta Obstet Gynecol Scand Suppl. 1983;113:177–185. doi: 10.3109/00016348309155224. [DOI] [PubMed] [Google Scholar]
  121. Lee J. B., Crowshaw K., Takman B. H., Attrep K. A. The identification of prostaglandins E(2), F(2alpha) and A(2) from rabbit kidney medulla. Biochem J. 1967 Dec;105(3):1251–1260. doi: 10.1042/bj1051251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  122. Levenson D. J., Simmons C. E., Jr, Brenner B. M. Arachidonic acid metabolism, prostaglandins and the kidney. Am J Med. 1982 Feb;72(2):354–374. doi: 10.1016/0002-9343(82)90826-9. [DOI] [PubMed] [Google Scholar]
  123. Levin D. L. Effects of inhibition of prostaglandin synthesis on fetal development, oxygenation, and the fetal circulation. Semin Perinatol. 1980 Jan;4(1):35–44. [PubMed] [Google Scholar]
  124. Levine L. Arachidonic acid transformation and tumor production. Adv Cancer Res. 1981;35:49–79. doi: 10.1016/s0065-230x(08)60908-2. [DOI] [PubMed] [Google Scholar]
  125. Lewis R. A., Austen K. F., Drazen J. M., Clark D. A., Marfat A., Corey E. J. Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci U S A. 1980 Jun;77(6):3710–3714. doi: 10.1073/pnas.77.6.3710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  126. Lewis R. A., Austen K. F. The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology. J Clin Invest. 1984 Apr;73(4):889–897. doi: 10.1172/JCI111312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  127. Lianos E. A., Andres G. A., Dunn M. J. Glomerular prostaglandin and thromboxane synthesis in rat nephrotoxic serum nephritis. Effects on renal hemodynamics. J Clin Invest. 1983 Oct;72(4):1439–1448. doi: 10.1172/JCI111100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  128. Ligumsky M., Karmeli F., Sharon P., Zor U., Cohen F., Rachmilewitz D. Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology. 1981 Sep;81(3):444–449. [PubMed] [Google Scholar]
  129. MacGlashan D. W., Jr, Schleimer R. P., Peters S. P., Schulman E. S., Adams G. K., 3rd, Newball H. H., Lichtenstein L. M. Generation of leukotrienes by purified human lung mast cells. J Clin Invest. 1982 Oct;70(4):747–751. doi: 10.1172/JCI110670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  130. Majerus P. W. Arachidonate metabolism in vascular disorders. J Clin Invest. 1983 Nov;72(5):1521–1525. doi: 10.1172/JCI111110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  131. Marcus A. J. Aspirin as an antithrombotic medication. N Engl J Med. 1983 Dec 15;309(24):1515–1517. doi: 10.1056/NEJM198312153092410. [DOI] [PubMed] [Google Scholar]
  132. Martin K., Zipser R., Horton R. Effect of prostaglandin inhibition on the hypertensive action of sodium-retaining steroids. Hypertension. 1981 Sep-Oct;3(5):622–628. doi: 10.1161/01.hyp.3.5.622. [DOI] [PubMed] [Google Scholar]
  133. Mathé A. A., Hedqvist P., Holmgren A., Svanborg N. Bronchial hyperreactivity to prostaglandin F 2 and histamine in patients with asthma. Br Med J. 1973 Jan 27;1(5847):193–196. doi: 10.1136/bmj.1.5847.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  134. Mathé A. A., Hedqvist P., Strandberg K., Leslie C. A. Aspects of prostaglandin function in the lung (second of two parts). N Engl J Med. 1977 Apr 21;296(16):910–914. doi: 10.1056/NEJM197704212961605. [DOI] [PubMed] [Google Scholar]
  135. Matuchansky C., Bernier J. J. Effect of prostaglandin E 1 on glucose, water, and electrolyte absorption in the human jejunum. Gastroenterology. 1973 Jun;64(6):1111–1118. [PubMed] [Google Scholar]
  136. McKeen C. R., Brigham K. L., Bowers R. E., Harris T. R. Pulmonary vascular effects of fat emulsion infusion in unanesthetized sheep. Prevention by indomethacin. J Clin Invest. 1978 May;61(5):1291–1297. doi: 10.1172/JCI109046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  137. Metz S. A. Anti-inflammatory agents as inhibitors of prostaglandin synthesis in man. Med Clin North Am. 1981 Jul;65(4):713–757. doi: 10.1016/s0025-7125(16)31495-x. [DOI] [PubMed] [Google Scholar]
  138. Metz S. A., McRae J. R., Robertson R. P. Prostaglandins as mediators of paraneoplastic syndromes: review and up-date. Metabolism. 1981 Mar;30(3):299–316. doi: 10.1016/0026-0495(81)90156-6. [DOI] [PubMed] [Google Scholar]
  139. Metz S., VanRollins M., Strife R., Fujimoto W., Robertson R. P. Lipoxygenase pathway in islet endocrine cells. Oxidative metabolism of arachidonic acid promotes insulin release. J Clin Invest. 1983 May;71(5):1191–1205. doi: 10.1172/JCI110868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  140. Miller T. A. Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am J Physiol. 1983 Nov;245(5 Pt 1):G601–G623. doi: 10.1152/ajpgi.1983.245.5.G601. [DOI] [PubMed] [Google Scholar]
  141. Minkin C., Fredericks R. S., Pokress S., Rude R. K., Sharp C. F., Jr, Tong M., Singer F. R. Bone resorption and humoral hypercalcemia of malignancy: stimulation of bone resorption in vitro by tumor extracts is inhibited by prostaglandin synthesis inhibitors. J Clin Endocrinol Metab. 1981 Nov;53(5):941–947. doi: 10.1210/jcem-53-5-941. [DOI] [PubMed] [Google Scholar]
  142. Mirouze D., Zipser R. D., Reynolds T. B. Effect of inhibitors of prostaglandin synthesis on induced diuresis in cirrhosis. Hepatology. 1983 Jan-Feb;3(1):50–55. doi: 10.1002/hep.1840030108. [DOI] [PubMed] [Google Scholar]
  143. Moncada S., Gryglewski R., Bunting S., Vane J. R. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976 Oct 21;263(5579):663–665. doi: 10.1038/263663a0. [DOI] [PubMed] [Google Scholar]
  144. Morrison A. R., Nishikawa K., Needleman P. Unmasking of thromboxane A2 synthesis by ureteral obstruction in the rabbit kidney. Nature. 1977 May 19;267(5608):259–260. doi: 10.1038/267259a0. [DOI] [PubMed] [Google Scholar]
  145. Mundy G. R., Ibbotson K. J., D'Souza S. M., Simpson E. L., Jacobs J. W., Martin T. J. The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms. N Engl J Med. 1984 Jun 28;310(26):1718–1727. doi: 10.1056/NEJM198406283102607. [DOI] [PubMed] [Google Scholar]
  146. Murphy R. C., Hammarström S., Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4275–4279. doi: 10.1073/pnas.76.9.4275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  147. Musch M. W., Miller R. J., Field M., Siegel M. I. Stimulation of colonic secretion by lipoxygenase metabolites of arachidonic acid. Science. 1982 Sep 24;217(4566):1255–1256. doi: 10.1126/science.6810465. [DOI] [PubMed] [Google Scholar]
  148. Nadler J. L., Velasco J. S., Horton R. Cigarette smoking inhibits prostacyclin formation. Lancet. 1983 Jun 4;1(8336):1248–1250. doi: 10.1016/s0140-6736(83)92698-3. [DOI] [PubMed] [Google Scholar]
  149. Needleman P., Raz A., Ferrendelli J. A., Minkes M. Application of imidazole as a selective inhibitor thromboxane synthetase in human platelets. Proc Natl Acad Sci U S A. 1977 Apr;74(4):1716–1720. doi: 10.1073/pnas.74.4.1716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  150. Northway M. G., Castell D. O. Do prostaglandins cause gastrointestinal mucosal injury? Dig Dis Sci. 1981 May;26(5):453–456. doi: 10.1007/BF01313590. [DOI] [PubMed] [Google Scholar]
  151. O'Grady J. P., Caldwell B. V., Auletta F. J., Speroff L. The effects of an inhibitor of prostaglandin synthesis (indomethacin) on ovulation, pregnancy, and pseudopregnancy in the rabbit. Prostaglandins. 1972 Feb;1(2):97–106. doi: 10.1016/0090-6980(72)90072-x. [DOI] [PubMed] [Google Scholar]
  152. ORLOFF J., HANDLER J. S., BERGSTROM S. EFFECT OF PROSTAGLANDIN (PGE-1) ON THE PERMEABILITY RESPONSE OF TOAD BLADDER TO VASOPRESSIN, THEOPHYLLINE AND ADENOSINE 3',5'-MONOPHOSPHATE. Nature. 1965 Jan 23;205:397–398. doi: 10.1038/205397a0. [DOI] [PubMed] [Google Scholar]
  153. Okegawa T., Jonas P. E., DeSchryver K., Kawasaki A., Needleman P. Metabolic and cellular alterations underlying the exaggerated renal prostaglandin and thromboxane synthesis in ureter obstruction in rabbits. Inflammatory response involving fibroblasts and mononuclear cells. J Clin Invest. 1983 Jan;71(1):81–90. doi: 10.1172/JCI110754. [DOI] [PMC free article] [PubMed] [Google Scholar]
  154. Owen P. R. Prostaglandin synthetase inhibitors in the treatment of primary dysmenorrhea. Outcome trials reviewed. Am J Obstet Gynecol. 1984 Jan 1;148(1):96–103. doi: 10.1016/s0002-9378(84)80039-3. [DOI] [PubMed] [Google Scholar]
  155. Patak R. V., Mookerjee B. K., Bentzel C. J., Hysert P. E., Babej M., Lee J. B. Antagonism of the effects of furosemide by indomethacin in normal and hypertensive man. Prostaglandins. 1975 Oct;10(4):649–659. doi: 10.1016/s0090-6980(75)80012-8. [DOI] [PubMed] [Google Scholar]
  156. Patrono C., Pugliese F., Ciabattoni G., Patrignani P., Maseri A., Chierchia S., Peskar B. A., Cinotti G. A., Simonetti B. M., Pierucci A. Evidence for a direct stimulatory effect of prostacyclin on renin release in man. J Clin Invest. 1982 Jan;69(1):231–239. doi: 10.1172/JCI110435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  157. Piper P. J., Samhoun M. N. The mechanism of action of leukotrienes C4 and D4 in guinea-pig isolated perfused lung and parenchymal strips of guinea pig, rabbit and rat. Prostaglandins. 1981 May;21(5):793–803. doi: 10.1016/0090-6980(81)90236-7. [DOI] [PubMed] [Google Scholar]
  158. Pitt B., Shea M. J., Romson J. L., Lucchesi B. R. Prostaglandins and prostaglandin inhibitors in ischemic heart disease. Ann Intern Med. 1983 Jul;99(1):83–92. doi: 10.7326/0003-4819-99-1-83. [DOI] [PubMed] [Google Scholar]
  159. Pomerantz K. B., Tall A. R., Feinmark S. J., Cannon P. J. Stimulation of vascular smooth muscle cell prostacyclin and prostaglandin E2 synthesis by plasma high and low density lipoproteins. Circ Res. 1984 May;54(5):554–565. doi: 10.1161/01.res.54.5.554. [DOI] [PubMed] [Google Scholar]
  160. Printz M. P., Skidgel R. A., Friedman W. F. Studies of pulmonary prostaglandin biosynthetic and catabolic enzymes as factors in ductus arteriosus patency and closure. Evidence for a shift in products with gestational age. Pediatr Res. 1984 Jan;18(1):19–24. [PubMed] [Google Scholar]
  161. Pulkkinen M. O. Prostaglandins and the non-pregnant uterus. The pathophysiology of primary dysmenorrhea. Acta Obstet Gynecol Scand Suppl. 1983;113:63–67. doi: 10.3109/00016348309155200. [DOI] [PubMed] [Google Scholar]
  162. Rachmilewitz D. Prostaglandins and diarrhea. Dig Dis Sci. 1980 Dec;25(12):897–899. doi: 10.1007/BF01308037. [DOI] [PubMed] [Google Scholar]
  163. Rampton D. S., Hawkey C. J. Prostaglandins and ulcerative colitis. Gut. 1984 Dec;25(12):1399–1413. doi: 10.1136/gut.25.12.1399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  164. Rampton D. S., Sladen G. E. Prostaglandin synthesis inhibitors in ulcerative colitis: flurbiprofen compared with conventional treatment. Prostaglandins. 1981 Mar;21(3):417–425. doi: 10.1016/0090-6980(81)90087-3. [DOI] [PubMed] [Google Scholar]
  165. Reines H. D., Halushka P. V., Cook J. A., Wise W. C., Rambo W. Plasma thromboxane concentrations are raised in patients dying with septic shock. Lancet. 1982 Jul 24;2(8291):174–175. doi: 10.1016/s0140-6736(82)91027-3. [DOI] [PubMed] [Google Scholar]
  166. Robert A., Nezamis J. E., Phillips J. P. Inhibition of gastric secretion by prostaglandins. Am J Dig Dis. 1967 Oct;12(10):1073–1076. doi: 10.1007/BF02233268. [DOI] [PubMed] [Google Scholar]
  167. Roberts L. J., 2nd, Sweetman B. J., Lewis R. A., Austen K. F., Oates J. A. Increased production of prostaglandin D2 in patients with systemic mastocytosis. N Engl J Med. 1980 Dec 11;303(24):1400–1404. doi: 10.1056/NEJM198012113032405. [DOI] [PubMed] [Google Scholar]
  168. Roberts L. J., 2nd, Sweetman B. J., Maas R. L., Hubbard W. C., Oates J. A. Clinical application of PG and TX metabolite quantification. Prog Lipid Res. 1981;20:117–121. doi: 10.1016/0163-7827(81)90023-0. [DOI] [PubMed] [Google Scholar]
  169. Robertson R. P. Arachidonic acid and metabolic diseases. Spec Top Endocrinol Metab. 1983;5:55–81. [PubMed] [Google Scholar]
  170. Robertson R. P., Baylink D. J., Metz S. A., Cummings K. B. Plasma prostaglandin E in patients with cancer with and without hypercalcemia. J Clin Endocrinol Metab. 1976 Dec;43(6):1330–1335. doi: 10.1210/jcem-43-6-1330. [DOI] [PubMed] [Google Scholar]
  171. Robertson R. P. Prostaglandins, glucose homeostasis, and diabetes mellitus. Annu Rev Med. 1983;34:1–12. doi: 10.1146/annurev.me.34.020183.000245. [DOI] [PubMed] [Google Scholar]
  172. Robertson R. P. Prostaglandins, glucose homeostasis, and diabetes mellitus. Med Clin North Am. 1981 Jul;65(4):759–771. doi: 10.1016/s0025-7125(16)31496-1. [DOI] [PubMed] [Google Scholar]
  173. Robinson D. R., Dayer J. M., Krane S. M. Prostaglandins and their regulation in rheumatoid inflammation. Ann N Y Acad Sci. 1979;332:279–294. doi: 10.1111/j.1749-6632.1979.tb47122.x. [DOI] [PubMed] [Google Scholar]
  174. Robinson D. R. Prostaglandins and anti-inflammatory drugs. Dis Mon. 1983 Dec;30(3):2–46. doi: 10.1016/s0011-5029(83)80002-9. [DOI] [PubMed] [Google Scholar]
  175. Rumpf K. W., Frenzel S., Lowitz H. D., Scheler F. The effect of indomethacin on plasma renin activity in man under normal conditions and after stimulation of the renin angiotensin system. Prostaglandins. 1975 Oct;10(4):641–648. doi: 10.1016/s0090-6980(75)80011-6. [DOI] [PubMed] [Google Scholar]
  176. SAMUELSSON B. ISOLATION AND IDENTIFICATION OF PROSTAGLANDINS FROM HUMAN SEMINAL PLASMA. 18. PROSTAGLANDINS AND RELATED FACTORS. J Biol Chem. 1963 Oct;238:3229–3234. [PubMed] [Google Scholar]
  177. Saldeen T. Clotting, microembolism, and inhibition of fibrinolysis in adult respiratory distress. Surg Clin North Am. 1983 Apr;63(2):285–304. doi: 10.1016/s0039-6109(16)42982-8. [DOI] [PubMed] [Google Scholar]
  178. Samuelsson B. From studies of biochemical mechanism to novel biological mediators: prostaglandin endoperoxides, thromboxanes, and leukotrienes. Nobel Lecture, 8 December 1982. Biosci Rep. 1983 Sep;3(9):791–813. doi: 10.1007/BF01133779. [DOI] [PubMed] [Google Scholar]
  179. Samuelsson B., Goldyne M., Granström E., Hamberg M., Hammarström S., Malmsten C. Prostaglandins and thromboxanes. Annu Rev Biochem. 1978;47:997–1029. doi: 10.1146/annurev.bi.47.070178.005025. [DOI] [PubMed] [Google Scholar]
  180. Samuelsson B., Granström E., Green K., Hamberg M., Hammarström S. Prostaglandins. Annu Rev Biochem. 1975;44:669–695. doi: 10.1146/annurev.bi.44.070175.003321. [DOI] [PubMed] [Google Scholar]
  181. Samuelsson B., Hammarström S. Leukotrienes: a novel group of biologically active compounds. Vitam Horm. 1982;39:1–30. doi: 10.1016/s0083-6729(08)61134-6. [DOI] [PubMed] [Google Scholar]
  182. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983 May 6;220(4597):568–575. doi: 10.1126/science.6301011. [DOI] [PubMed] [Google Scholar]
  183. Serhan C. N., Hamberg M., Samuelsson B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci U S A. 1984 Sep;81(17):5335–5339. doi: 10.1073/pnas.81.17.5335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  184. Seyberth H. W., Segre G. V., Morgan J. L., Sweetman B. J., Potts J. T., Jr, Oates J. A. Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. N Engl J Med. 1975 Dec 18;293(25):1278–1283. doi: 10.1056/NEJM197512182932502. [DOI] [PubMed] [Google Scholar]
  185. Sharon P., Ligumsky M., Rachmilewitz D., Zor U. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology. 1978 Oct;75(4):638–640. [PubMed] [Google Scholar]
  186. Sharon P., Stenson W. F. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology. 1984 Mar;86(3):453–460. [PubMed] [Google Scholar]
  187. Sharon P., Stenson W. F. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology. 1984 Mar;86(3):453–460. [PubMed] [Google Scholar]
  188. Sharon P., Stenson W. F. Metabolism of arachidonic acid in acetic acid colitis in rats. Similarity to human inflammatory bowel disease. Gastroenterology. 1985 Jan;88(1 Pt 1):55–63. doi: 10.1016/s0016-5085(85)80132-3. [DOI] [PubMed] [Google Scholar]
  189. Siegel M. I., McConnell R. T., Cuatrecasas P. Aspirin-like drugs interfere with arachidonate metabolism by inhibition of the 12-hydroperoxy-5,8,10,14-eicosatetraenoic acid peroxidase activity of the lipoxygenase pathway. Proc Natl Acad Sci U S A. 1979 Aug;76(8):3774–3778. doi: 10.1073/pnas.76.8.3774. [DOI] [PMC free article] [PubMed] [Google Scholar]
  190. Siegel M. I., McConnell R. T., Porter N. A., Selph J. L., Truax J. F., Vinegar R., Cuatrecasas P. Aspirin-like drugs inhibit arachidonic acid metabolism via lipoxygenase and cyclo-oxygenase in rat neutrophils from carrageenan pleural exudates. Biochem Biophys Res Commun. 1980 Jan 29;92(2):688–695. doi: 10.1016/0006-291x(80)90388-5. [DOI] [PubMed] [Google Scholar]
  191. Silver M. J. Mechanisms of hemostasis and therapy of thrombosis: new concepts based on the metabolism of arachidonic acid by platelets and endothelial cells. Adv Pharmacol Chemother. 1981;18:1–47. doi: 10.1016/s1054-3589(08)60253-7. [DOI] [PubMed] [Google Scholar]
  192. Simmons P. M., Salmon J. A., Moncada S. The release of leukotriene B4 during experimental inflammation. Biochem Pharmacol. 1983 Apr 15;32(8):1353–1359. doi: 10.1016/0006-2952(83)90446-x. [DOI] [PubMed] [Google Scholar]
  193. Simon L. S., Mills J. A. Nonsteroidal antiinflammatory drugs (second of two parts). N Engl J Med. 1980 May 29;302(22):1237–1243. doi: 10.1056/NEJM198005293022206. [DOI] [PubMed] [Google Scholar]
  194. Speckart P., Zia P., Zipser R., Horton R. The effect of sodium restriction and prostaglandin inhibition on the renin-angiotensin system in man. J Clin Endocrinol Metab. 1977 May;44(5):832–837. doi: 10.1210/jcem-44-5-832. [DOI] [PubMed] [Google Scholar]
  195. Stenson W. F., Lobos E. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J Clin Invest. 1982 Feb;69(2):494–497. doi: 10.1172/JCI110474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  196. Stillman M. T., Napier J., Blackshear J. L. Adverse effects of nonsteroidal anti-inflammatory drugs on the kidney. Med Clin North Am. 1984 Mar;68(2):371–385. doi: 10.1016/s0025-7125(16)31136-1. [DOI] [PubMed] [Google Scholar]
  197. Stokes J. B., Kokko J. P. Inhibition of sodium transport by prostaglandin E2 across the isolated, perfused rabbit collecting tubule. J Clin Invest. 1977 Jun;59(6):1099–1104. doi: 10.1172/JCI108733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  198. Stuart M. J., Gerrard J. M., White J. G. Effect of cholesterol on production of thromboxane b2 by platelets in vitro. N Engl J Med. 1980 Jan 3;302(1):6–10. doi: 10.1056/NEJM198001033020102. [DOI] [PubMed] [Google Scholar]
  199. Szczeklik A., Gryglewski R. J., Czerniawska-Mysik G. Clinical patterns of hypersensitivity to nonsteroidal anti-inflammatory drugs and their pathogenesis. J Allergy Clin Immunol. 1977 Nov;60(5):276–284. doi: 10.1016/0091-6749(77)90106-3. [DOI] [PubMed] [Google Scholar]
  200. Szczeklik A., Nizankowski R., Skawinski S., Szczeklik J., Gluszko P., Gryglewski R. J. Successful therapy of advanced arteriosclerosis obliterans with prostacyclin. Lancet. 1979 May 26;1(8126):1111–1114. doi: 10.1016/s0140-6736(79)91792-6. [DOI] [PubMed] [Google Scholar]
  201. Tan S. Y., Shapiro R., Franco R., Stockard H., Mulrow P. J. Indomethacin-induced prostaglandin inhibition with hyperkalemia. A reversible cause of hyporeninemic hypoaldosteronism. Ann Intern Med. 1979 May;90(5):783–785. doi: 10.7326/0003-4819-90-5-783. [DOI] [PubMed] [Google Scholar]
  202. Tan S. Y., Shapiro R., Kish M. A. Reversible acute renal failure induced by indomethacin. JAMA. 1979 Jun 22;241(25):2732–2733. [PubMed] [Google Scholar]
  203. Tisdale M. J. Role of prostaglandins in metastatic dissemination of cancer. Minireview on cancer research. Exp Cell Biol. 1983;51(5):250–256. doi: 10.1159/000163200. [DOI] [PubMed] [Google Scholar]
  204. Turney J. H., Williams L. C., Fewell M. R., Parsons V., Weston M. J. Platelet protection and heparin sparing with prostacyclin during regular dialysis therapy. Lancet. 1980 Aug 2;2(8188):219–222. doi: 10.1016/s0140-6736(80)90116-6. [DOI] [PubMed] [Google Scholar]
  205. Tyler H. M., Saxton C. A., Parry M. J. Administration to man of UK-37,248-01, a selective inhibitor of thromboxane synthetase. Lancet. 1981 Mar 21;1(8221):629–632. doi: 10.1016/s0140-6736(81)91551-8. [DOI] [PubMed] [Google Scholar]
  206. Usberti M., Dechaux M., Guillot M., Seligmann R., Pavlovitch H., Loirat C., Sachs C., Broyer M. Renal prostaglandin E2 in nephrogenic diabetes insipidus: effects of inhibition of prostaglandin synthesis by indomethacin. J Pediatr. 1980 Sep;97(3):476–478. doi: 10.1016/s0022-3476(80)80211-3. [DOI] [PubMed] [Google Scholar]
  207. Utsonomiya T., Krausz M. M., Levine L., Shepro D., Hechtman H. B. Thromboxane mediation of cardiopulmonary effects of embolism. J Clin Invest. 1982 Aug;70(2):361–368. doi: 10.1172/JCI110625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  208. VAN DORPD, BEERTHUIS R. K., NUGTEREN D. H., VONKEMAN H. THE BIOSYNTHESIS OF PROSTAGLANDINS. Biochim Biophys Acta. 1964 Jul 15;90:204–207. doi: 10.1016/0304-4165(64)90144-8. [DOI] [PubMed] [Google Scholar]
  209. Vane J. R. Clinical potential of prostacyclin. Adv Prostaglandin Thromboxane Leukot Res. 1983;11:449–456. [PubMed] [Google Scholar]
  210. Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232–235. doi: 10.1038/newbio231232a0. [DOI] [PubMed] [Google Scholar]
  211. Veldhuis J. D., Bardin C. W., Demers L. M. Metabolic mimicry of Bartter's syndrome by covert vomiting: utility of urinary chloride determinations. Am J Med. 1979 Feb;66(2):361–363. doi: 10.1016/0002-9343(79)90566-7. [DOI] [PubMed] [Google Scholar]
  212. Verberckmoes R., van Damme B B., Clement J., Amery A., Michielsen P. Bartter's syndrome with hyperplasia of renomedullary cells: successful treatment with indomethacin. Kidney Int. 1976 Mar;9(3):302–307. doi: 10.1038/ki.1976.33. [DOI] [PubMed] [Google Scholar]
  213. Voelkel E. F., Tashjian A. H., Jr, Franklin R., Wasserman E., Levine L. Hypercalcemia and tumor-prostaglandins: the VX2 carcinoma model in the rabbit. Metabolism. 1975 Aug;24(8):973–986. doi: 10.1016/0026-0495(75)90089-x. [DOI] [PubMed] [Google Scholar]
  214. Wada T., Ishizawa M. [Effects of prostaglandin on the function of the gastric secretion]. Nihon Rinsho. 1970 Oct;28(10):2465–2468. [PubMed] [Google Scholar]
  215. Walker I. D., Davidson J. F., Faichney A., Wheatley D. J., Davidson K. G. A double blind study of prostacyclin in cardiopulmonary bypass surgery. Br J Haematol. 1981 Nov;49(3):415–423. doi: 10.1111/j.1365-2141.1981.tb07244.x. [DOI] [PubMed] [Google Scholar]
  216. Watkins W. D., Peterson M. B., Crone R. K., Shannon D. C., Levine L. Prostacyclin and prostaglandin E1 for severe idiopathic pulmonary artery hypertension. Lancet. 1980 May 17;1(8177):1083–1083. doi: 10.1016/s0140-6736(80)91522-6. [DOI] [PubMed] [Google Scholar]
  217. Weiss J. W., Drazen J. M., Coles N., McFadden E. R., Jr, Weller P. F., Corey E. J., Lewis R. A., Austen K. F. Bronchoconstrictor effects of leukotriene C in humans. Science. 1982 Apr 9;216(4542):196–198. doi: 10.1126/science.7063880. [DOI] [PubMed] [Google Scholar]
  218. Whittle B. J., Higgs G. A., Eakins K. E., Moncada S., Vane J. R. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature. 1980 Mar 20;284(5753):271–273. doi: 10.1038/284271a0. [DOI] [PubMed] [Google Scholar]
  219. Whittle B. J., Moncada S. Pharmacological interactions between prostacyclin and thromboxanes. Br Med Bull. 1983 Jul;39(3):232–238. doi: 10.1093/oxfordjournals.bmb.a071825. [DOI] [PubMed] [Google Scholar]
  220. Wilson D. E., Kaymakcalan H. Prostaglandins: gastrointestinal effects and peptic ulcer disease. Med Clin North Am. 1981 Jul;65(4):773–787. doi: 10.1016/s0025-7125(16)31497-3. [DOI] [PubMed] [Google Scholar]
  221. Wilson D. E., Phillips C., Levine R. A. Inhibition of gastric secretion in man by prostaglandin A. Gastroenterology. 1971 Aug;61(2):201–206. [PubMed] [Google Scholar]
  222. Zipser R. D., Hoefs J. C., Speckart P. F., Zia P. K., Horton R. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab. 1979 Jun;48(6):895–900. doi: 10.1210/jcem-48-6-895. [DOI] [PubMed] [Google Scholar]
  223. Zipser R. D., Kronborg I., Rector W., Reynolds T., Daskalopoulos G. Therapeutic trial of thromboxane synthesis inhibition in the hepatorenal syndrome. Gastroenterology. 1984 Dec;87(6):1228–1232. [PubMed] [Google Scholar]
  224. Zipser R. D., Radvan G. H., Kronborg I. J., Duke R., Little T. E. Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors. Gastroenterology. 1983 Apr;84(4):697–703. [PubMed] [Google Scholar]
  225. Zipser R. D., Rude R. K., Zia P. K., Fichman M. P. Regulation of urinary prostaglandins in Bartter's syndrome. Am J Med. 1979 Aug;67(2):263–267. doi: 10.1016/0002-9343(79)90401-7. [DOI] [PubMed] [Google Scholar]
  226. Zipser R. D., Zia P., Stone R. A., Horton R. The prostaglandin and kallikrein-kinin systems in mineralocorticoid escape. J Clin Endocrinol Metab. 1978 Nov;47(5):996–1001. doi: 10.1210/jcem-47-5-996. [DOI] [PubMed] [Google Scholar]
  227. Zipser R., Myers S., Needleman P. Exaggerated prostaglandin and thromboxane synthesis in the rabbit with renal vein constriction. Circ Res. 1980 Aug;47(2):231–237. doi: 10.1161/01.res.47.2.231. [DOI] [PubMed] [Google Scholar]
  228. Zusman R. M., Keiser H. R., Handler J. S. Vasopressin-stimulated prostaglandin E biosynthesis in the toad urinary bladder. Effect of water flow. J Clin Invest. 1977 Dec;60(6):1339–1347. doi: 10.1172/JCI108893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  229. Zusman R. M. Prostaglandins, vasopressin, and renal water reabsorption. Med Clin North Am. 1981 Jul;65(4):915–925. doi: 10.1016/s0025-7125(16)31505-x. [DOI] [PubMed] [Google Scholar]
  230. Zusman R. M., Spector D., Caldwell B. V., Speroff L., Schneider G., Mulbow P. J. The effect of chronic sodium loading and sodium restriction on plasma prostaglandin A, E, and F concentrations in normal humans. J Clin Invest. 1973 May;52(5):1093–1098. doi: 10.1172/JCI107274. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES